Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
The treatment landscape of HR-positive, HER2-negative breast cancer is evolving constantly in the adjuvant as well as the metastatic settings. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Renal Cell Carcinoma
To offer optimal care to patients with RCC, clinicians must have a deep understanding of the key trial results and know how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates in the Treatment of Metastatic Urothelial Cancer
Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer
For some patients with localized prostate cancer, the treatment approach is determined by patient and disease characteristics. For others, advanced risk stratification with gene expression profiling or AI-derived digital histopathology biomarkers can help identify those who may derive greater or lesser absolute benefit from a given treatment, thus informing treatment decisions and reducing the chances of over- or under-treatment.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates to the Management of Cutaneous Melanoma
Despite recent advances in immunotherapies and targeted therapies for patients with advanced melanoma, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and the need for better early diagnosis. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will benefit clinicians in selecting treatment options for patients with melanoma.
Category
  • Melanoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates to the Management of Endometrial Cancer
Comprehensive knowledge in this topic will guide practitioners in providing appropriate treatment to improve patient outcomes.
Category
  • Gynecologic Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status
While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.
Category
  • Skin Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Plenary Session - Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care
Cancer drug shortages have had a significant impact on clinical practice with much confusion around how to appropriately manage care of patients with cancer in the midst of a drug shortage. You can benefit by learning what you can do both in your practice and in your advocacy to advance short-term and long-term solutions.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors
The goal of this initiative is to provide education to assist clinicians in providing appropriate care for patients with non-small cell lung cancer (NSCLC) through a greater understanding of the significance of biomarker testing to predict treatment response, the role of PD-1/PD-L1 inhibitors in
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.75 AAPA Category 1 CME credit
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC contact hours
  • 1.75 Participation

Pages